This content is only available within our institutional offering.
18 Mar 2020
LIBERUM: Healthcare - Anchor points through COVID-19
Cello Health (CLL:LON), 0 | Futura Medical plc (FUM:LON), 36.0 | Huntsworth (HNT:LON), 0 | Malin Corporation PLC (MLC:DUB), 0 | Oxford BioMedica plc (OXB:LON), 218 | PureTech Health PLC (PRTC:LON), 212 | Spire Healthcare Group PLC (SPI:LON), 247 | AstraZeneca PLC (AZN:LON), 11,349 | Bayer AG (BAYN:ETR), 0 | Novartis AG (NOVN:SWX), 0 | Novo Nordisk A/S Class B (NOVO.B:CSE), 0 | Roche Holding Ltd Dividend Right Cert. (ROG:SWX), 0 | Sanofi (SAN:PAR), 0
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
LIBERUM: Healthcare - Anchor points through COVID-19
Cello Health (CLL:LON), 0 | Futura Medical plc (FUM:LON), 36.0 | Huntsworth (HNT:LON), 0 | Malin Corporation PLC (MLC:DUB), 0 | Oxford BioMedica plc (OXB:LON), 218 | PureTech Health PLC (PRTC:LON), 212 | Spire Healthcare Group PLC (SPI:LON), 247 | AstraZeneca PLC (AZN:LON), 11,349 | Bayer AG (BAYN:ETR), 0 | Novartis AG (NOVN:SWX), 0 | Novo Nordisk A/S Class B (NOVO.B:CSE), 0 | Roche Holding Ltd Dividend Right Cert. (ROG:SWX), 0 | Sanofi (SAN:PAR), 0
- Published:
18 Mar 2020 -
Author:
Graham Doyle | Alistair Campbell -
Pages:
22